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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comlesions, 15 had type 2 appearance, and 7 had type 3. The mean angiographic stenosis
in the 22 lesions was 75.4  17.0%, varying from mild stenosis to complete occlusion
(ranging from 40-100%). Dissected segments were long with mean length 45.6 
30.8mm, especially in patients with type 2 SCAD (mean length 56.7  31.4mm).
TIMI ﬂow was 3 in 17/22, 2 in 1/22, 1 in 1/22, and 0 in 2/22. All 10/10 SCAD arteries
evaluated on repeat coronary angiography showed spontaneous arterial healing.
Conclusions: Intracoronary imaging conﬁrmed that SCAD may appear angiograph-
ically without multiple radiolucent lumen. In fact, the angiographic stenosis can be
long and diffuse, or mimic atherosclerosis. Angiographers should be familiar with
such angiographic variants to improve SCAD diagnosis.
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Background: Polymorphisms in platelet receptor genes may inﬂuence platelet
function. This study aimed to assess the impact of 5 polymorphisms of genes encoding
platelet receptors on the risk of ischemic and bleeding events in ST-elevation
myocardial infarction (STEMI) patients after percutaneous coronary intervention
(PCI).
Methods: 503 consecutive Chinese patients with STEMI after an uneventful PCI and
exposed to standard dual antiplatelet therapy for 12 months, were enrolled in the
single-center registry. Polymorphisms of platelet receptors, GPIa (rs1126643),
GPIV(rs1613662), PAR-1 (rs168753) and P2Y12 (rs6785930, rs6809699) were
detected by the ligase detection reaction. The primary clinical efﬁcacy end point was a
composite of cardiovascular death, non-fatal myocardial infarction, unplanned target
vessel revascularization, and stent thrombosis. The primary clinical safety end point
was the incidence of major bleedings deﬁned according to the Bleeding Academic
Research Consortium (BARC) criteria, including type 3 and 5 in the analysis. The
follow-up period was 12 months.
Results: Overall, 33 (6.6%) ischemic events occurred and 43 (8.5%) major bleedings
occurred, including 12 patients (2.4%) with BARC type 3b bleeding, 31 patients
(6.2%) with BARC type 3a bleeding. Multivariate Cox regression analysis showed the
carriage of PAR-1 rs168753 allele was an independent predictor of the composite
ischemic events (HR 0.455, 95%CI 0.224-0.924, p¼0.029) after adjusted for estab-
lished risk factors. Multivariate logistic regression model identiﬁed that carriage of
P2Y12 6785930 (OR 1.96, 95%CI 1.02-3.77, P¼0.044) and rs6809699 (OR 2.523,
95%CI 1.262-5.044, P¼0.009) were independent predictors of major bleedings. The
results were then validated in a second cohort of 510 STEMI patients after PCI.
Conclusions: In STEMI patients after PCI, PAR-1 rs168753 allele could signiﬁcantly
contribute to the risk of ischemic events, and P2Y12 rs6785930 and rs6809699 alleles
could predict bleedings. The genetic testing of platelet receptors can be valuable in
predicting adverse events in STEMI patients after PCI.
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Background: The STENTYS Self-Apposing stent has shown superior stent appo-
sition after primary PCI compared with a balloon-expandable stent (APPOSITION II
trial). APPOSITION III is the largest registry ever evaluating the use of a self-
expanding stent in the setting of primary PCI in 965 patients.
Methods: APPOSITON III is an international, prospective, multi-center, observa-
tional study (n¼965). Endpoints were the following: major adverse cardiac event
(MACE), deﬁned as the composite of cardiac death, target-vessel myocardial infarc-
tion (TV-MI), and clinically-driven target lesion revascularization (CD-TLR); the
individual MACE components; and stent thrombosis (ST) according to the ARC
deﬁnitions, at 2 years follow-up. All potential MACE were adjudicated by an inde-
pendent Clinical Event Committee.
Results: Two-year MACE rate was 11.2%. The cumulative event rates of the MACE
components were 2.3% (cardiac death), 2.3% (TV-MI), and 9.2% (CD-TLR). Prob-
able/deﬁnite ST rate was 3.9% (deﬁnite ST 3.3%) at two years. Patients undergoing
post-dilation showed lower MACE (10.4%), cardiac death (1.8%), TV-MI (1.9%),B4 JACC Vol 64/11/Suppl B jCD-TLR (8.4%), and deﬁnite/probable ST (2.8%) rates at 2 years. The beneﬁt
of post-dilatation was achieved early (i.e. < 30 days), as shown with a landmark
analysis (ﬁgure). Most events >30 days were CD-TLR (CD-TLR rate >30 days
< 2 years: 6.9%), with only few probable/deﬁnite ST in the same time period
(right ﬁgure).Conclusions: The use of STENTYS Self-Apposing stent during primary PCI is safe
and feasible. Follow-up at 2 years shows low event rates beyond the 30-day landmark.
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Background: Although previous studies have suggested clinical beneﬁts of complete
revascularization in patients with multivessel coronary artery disease, it is still
controversial whether preventive percutaneous coronary intervention (PCI) leads to
better clinical outcomes in the clinical setting of ST-segment elevation myocardial
infarction (STEMI).
Methods: Relevant studies published through March 2014 were searched and iden-
tiﬁed in the electronic databases. Primary endpoint was all-cause mortality at the
longest follow-up.
Results: From 836 initial citations, 6 randomized trials and 23 observational studies
with 43,960 patients (7,937 preventive and 36,023 culprit-only) were included in this
study. There were no signiﬁcant differences in all-cause mortality (odds ratios [OR],
1.01; 95% CI, 0.77–1.32; p ¼ 0.94), MI (OR, 1.12; 95% CI, 0.63–1.99; p ¼ 0.70), and
repeat revascularization (OR, 0.72;95% CI, 0.51–1.02; p ¼ 0.07) between the two
groups. Comparison of preventive PCI versus culprit-only PCI group disclosed ORs
for MACE of 0.83 (95% CI, 0.59–1.18; p ¼ 0.31). Stratiﬁed analysis according to the
different strategy demonstrated a signiﬁcantly lower incidence of all-cause mortality
with staged PCI compared with culprit-only or multivessel PCI during the index
procedure.Conclusions: Preventive PCI strategy did not reduce adverse outcomes when
compared with culprit-only revascularization in STEMI patients with multivessel
disease, while a signiﬁcantly lower all-cause mortality was observed with staged PCI
compared with culprit-only PCI or multivessel PCI during the index revascularization.September 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
